UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,767	08/08/2006	Guillaume Becard	0509-1107	4666
466 YOUNG & TH	7590 09/09/200 OMPSON	EXAMINER		
209 Madison St		PARA, ANNETTE H		
	Suite 500 ALEXANDRIA, VA 22314			PAPER NUMBER
			1661	
			MAIL DATE	DELIVERY MODE
			09/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comments	10/588,767	BECARD ET AL.				
Office Action Summary	Examiner	Art Unit				
	ANNETTE H PARA	1661				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	-· action is non-final.					
<i>,</i> —	, <del></del>					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>23-44</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 23-44 are subject to restriction and/or						
Application Papers						
9)☐ The specification is objected to by the Examiner	•					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
		7,66,67,67,167,17,7,67,62				
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>						
3. Copies of the certified copies of the prior	•	ed in this National Stage				
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application 6) Other:						
	,					

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Groups I-XVI, claim(s)s 23-30 (in part), drawn to a method of treating arbuscular mycorrhyizal fungi that utilizes a specified agent and a specified fungi; wherein the specified fungi for groups I-VIII is Glomus intraradices and the specified fungi for groups IX-XVI is Gigaspora rosea; and the specified agent for groups I and IX is GR24, for groups II and X is GR7, for groups III and XI is Njimegen 1, for groups IV and XII is Demethylsorgolactone, for groups V and XIII is strigol, for groups VI and XIV is sorgolactone, for groups VIII and XV is alectrol, and for groups VIII and XVI is orobanchol.

Application/Control Number: 10/588,767

Art Unit: 1638

Groups XVII-XXIV, claim(s) 31 and 32 (in part), drawn to a method of producing inoculum of arbuscular mycorrhizal fungi that utilizes a specified stimulating agent; wherein the specified stimulating agent for group XVII is GR24, for group XVIII is GR7, for group XIX is Njimegen 1, for group XX is Demethylsorgolactone, for group XXI is strigol, for group XXII is sorgolactone, for group XXIII is alectrol, and for group XXIV is orobanchol.

Groups XXV – XXXII, claim(s) 33-38 (in part), drawn to a method of cultivating a host plant capable of forming a symbiosis with arbuscular mycorrhyzal fungi, wherein said method utilizes a specified agent; and wherein the specified agent for group XXV is GR24, for group XXVII is GR7, for group XXVII is Njimegen 1, for group XXVIII is Demethylsorgolactone, for group XXIX is strigol, for group XXX is sorgolactone, for group XXXI is alectrol, and for group XXXII is orobanchol.

Groups XXXIII – XLVIII, claim(s) 39 – 44 (in part), drawn to a composition comprising seeds of a host plant, a specified agent, and a fungus inoculum; wherein the fungus for groups XXXIII-XL is Glomus intraradices and the specified fungus for groups XLI-XLVIII is Gigaspora rosea; and the specified agent for groups XXXIII and XLI is GR24, for groups XXXIV and XLII is GR7, for groups XXXV and XLIII is Njimegen 1, for groups XXXVII and XLIV is Demethylsorgolactone, for groups

Application/Control Number: 10/588,767

Art Unit: 1638

XXXVII and XLV is strigol, for groups XXXVIII and XLVI is sorgolactone, for groups XXXIX and XLVII is alectrol, and for groups XL and XLVIII is orobanchol.

2. The inventions listed as Groups I-XLVIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups I-XLVIII is an arbuscular mycorrhyzal fungi, a host, and a chemical agent. However, in the prior art (Applied and Environmental Microbiology (1989) Vol. 55; pp. 2320-2325) and (Applied and Environmental Microbiology (1987); Vol. 53; pp. 1928-1933), Becard et al and Elias et al teach that fungal growth is stimulated by root exudates in vesiculararbuscular mycorrhyzal symbiosis (see both documents); and Elias specifically teaches exudates from clover (*Trifolium*). Also in the prior art (Phytochemistry (1993) Vol. 49; 99. 1967-1973), Yokota et al teach that alectrol and orobanchol are components in the root exudates from *Trifolium* (see entire article). Taken together, one of ordinary skill in the art would have been motivated to utilize chemicals that are known to be components in the root exudates of clover to stimulate the growth of fungi; demonstrating that the technical feature linking the inventions lacks an inventive step over the prior art. Therefore, the technical feature linking the inventions of groups I-XLVIII does not constitute a special technical feature as defined by PCT Rule 13.2 as it does not define a contribution over the prior art.

Accordingly, Groups I-XLVIII are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104.

Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting

Application/Control Number: 10/588,767 Page 7

Art Unit: 1638

rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

/Annette H. Para/

Primary Examiner, Art Unit 1661